95,961 Shares in AngioDynamics, Inc. (NASDAQ:ANGO) Acquired by Principal Financial Group Inc.

Principal Financial Group Inc. bought a new stake in AngioDynamics, Inc. (NASDAQ:ANGO) during the fourth quarter, Holdings Channel reports. The firm bought 95,961 shares of the medical instruments supplier’s stock, valued at approximately $879,000.

Several other large investors have also made changes to their positions in the business. Rhumbline Advisers increased its holdings in shares of AngioDynamics by 1.7% during the 4th quarter. Rhumbline Advisers now owns 60,479 shares of the medical instruments supplier’s stock worth $554,000 after purchasing an additional 1,021 shares during the period. White Pine Capital LLC boosted its position in AngioDynamics by 189.6% in the fourth quarter. White Pine Capital LLC now owns 64,033 shares of the medical instruments supplier’s stock valued at $587,000 after buying an additional 41,925 shares in the last quarter. R Squared Ltd bought a new position in AngioDynamics in the 4th quarter valued at $49,000. SG Americas Securities LLC grew its holdings in AngioDynamics by 21.3% during the 4th quarter. SG Americas Securities LLC now owns 16,102 shares of the medical instruments supplier’s stock worth $147,000 after acquiring an additional 2,832 shares during the last quarter. Finally, Moody National Bank Trust Division increased its stake in shares of AngioDynamics by 70.2% in the 4th quarter. Moody National Bank Trust Division now owns 55,780 shares of the medical instruments supplier’s stock valued at $511,000 after buying an additional 23,003 shares during the period. Institutional investors and hedge funds own 89.43% of the company’s stock.

Insider Activity

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of the business’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total transaction of $49,978.60. Following the transaction, the senior vice president now directly owns 41,817 shares in the company, valued at approximately $514,767.27. The trade was a 8.85 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Separately, HC Wainwright lifted their price target on shares of AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, January 10th.

AngioDynamics Stock Performance

ANGO opened at $9.41 on Friday. AngioDynamics, Inc. has a twelve month low of $5.26 and a twelve month high of $13.50. The firm has a market cap of $380.79 million, a PE ratio of -1.67 and a beta of 0.60. The firm’s fifty day moving average is $10.83 and its two-hundred day moving average is $8.56.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.07. The firm had revenue of $72.90 million for the quarter, compared to the consensus estimate of $70.93 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The business’s quarterly revenue was down .1% on a year-over-year basis. During the same period last year, the company posted ($0.05) EPS. Equities analysts forecast that AngioDynamics, Inc. will post -0.37 EPS for the current fiscal year.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.